Active drug shortages have continued to plague the healthcare sector for the third consecutive quarter. A recent report from ajmc.com highlights that the scarcity of Ifosfamide poses significant challenges, especially concerning curative and salvage protocols. This shortage extends beyond testicular cancer and sarcoma treatments to include regimens such as RICE used in diffuse large B-cell lymphoma (DLBCL). The situation is described as chronic and fragile, impacting generic sterile injectable medications. [1] ajmc.com (2026-08-01 19:39)